On April 29, 2011, Abbott received approval for Androgel
(testosterone) 1.62%. Androgel 1% has been available since February of 2000. Both
strengths are approved to restore testosterone in hypogonadal males. The purpose of the
Androgel 1.62% is to produce the same results with half the volume ,
Dosing 1%: 50-100 mg every
(available in gel packets and pump)
Dosing 1.62%: 20.25-81 mg every
(available only in pump)
- Abbott. Abbott Receives U.S. FDA Approval for AndroGel® 1.62% to Treat Men with
Low Testosterone. Abbott.com. 29 Apr. 2011. Web. 27 July 2011.
1.62% [package insert]. North Chicago, IL: Abbott Laboratories.
On May 24, 2011 the
FDA approved a new strength of Zyclara which offers clinicians greater flexibility when treating
patients with imiquimod therapy. Zyclara 2.5% has been approved for actinic keratoses(AK).
The 3.75% cream was approved in March of this year and has an additional indication for both
genital and perianal warts. The main advantage of the 2.5% concentration is efficacy of the
product with better tolerability to the most common side effect of imiquimod agents, local skin
- "FDA Approves Zyclara® (imiquimod) Cream, 2.5%." Graceway
Pharmaceuticals, LLC. 19 July 2011. Web. 26 July 2011.
- Zyclara[package insert]. Graceway Pharmaceuticals, LLC., Bristol, TN;
March 2011. http://www.gracewaypharma.com/sites/default/files/products/Zyclara%20Full%20PI.pdf.
Accessed July 27, 2011.